CN1360503A - 用于治疗癌症的海鞘素743的组合物和用途 - Google Patents

用于治疗癌症的海鞘素743的组合物和用途 Download PDF

Info

Publication number
CN1360503A
CN1360503A CN00809976A CN00809976A CN1360503A CN 1360503 A CN1360503 A CN 1360503A CN 00809976 A CN00809976 A CN 00809976A CN 00809976 A CN00809976 A CN 00809976A CN 1360503 A CN1360503 A CN 1360503A
Authority
CN
China
Prior art keywords
cancer
patients
treating
administering
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00809976A
Other languages
English (en)
Chinese (zh)
Inventor
E·维科维克
G·D·德梅特里
C·古兹曼
J·吉门奥
L·罗佩兹拉扎罗
J·L·米斯瑟特
C·特威维斯
D·D·冯霍夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911183.3A external-priority patent/GB9911183D0/en
Priority claimed from GBGB9911346.6A external-priority patent/GB9911346D0/en
Priority claimed from GBGB9918534.0A external-priority patent/GB9918534D0/en
Priority claimed from GBGB9927005.0A external-priority patent/GB9927005D0/en
Priority claimed from GBGB9927106.6A external-priority patent/GB9927106D0/en
Priority claimed from GB0007637A external-priority patent/GB0007637D0/en
Application filed by Pharmamar SA filed Critical Pharmamar SA
Publication of CN1360503A publication Critical patent/CN1360503A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
CN00809976A 1999-05-13 2000-05-15 用于治疗癌症的海鞘素743的组合物和用途 Pending CN1360503A (zh)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
GBGB9911183.3A GB9911183D0 (en) 1999-05-13 1999-05-13 Treatment of cancers
GB9911183.3 1999-05-13
GBGB9911346.6A GB9911346D0 (en) 1999-05-14 1999-05-14 Treatment of cancers
GB9911346.6 1999-05-14
GBGB9918534.0A GB9918534D0 (en) 1999-08-05 1999-08-05 Treatment of cancers
GB9918534.0 1999-08-05
GBGB9927005.0A GB9927005D0 (en) 1999-11-15 1999-11-15 Treatment of cancers
GB9927005.0 1999-11-15
GB9927106.6 1999-11-16
GBGB9927106.6A GB9927106D0 (en) 1999-11-16 1999-11-16 Cancer treatment
GB0007637A GB0007637D0 (en) 2000-03-29 2000-03-29 Antitumour compound
GB0007637.2 2000-03-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CNB2005100091622A Division CN100477993C (zh) 1999-05-13 2000-05-15 用于治疗癌症的海鞘素743的组合物和用途
CNA2007101863681A Division CN101181272A (zh) 1999-05-13 2000-05-15 用于治疗癌症的海鞘素743的组合物和用途

Publications (1)

Publication Number Publication Date
CN1360503A true CN1360503A (zh) 2002-07-24

Family

ID=27546594

Family Applications (2)

Application Number Title Priority Date Filing Date
CN00809976A Pending CN1360503A (zh) 1999-05-13 2000-05-15 用于治疗癌症的海鞘素743的组合物和用途
CNB2005100091622A Expired - Lifetime CN100477993C (zh) 1999-05-13 2000-05-15 用于治疗癌症的海鞘素743的组合物和用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB2005100091622A Expired - Lifetime CN100477993C (zh) 1999-05-13 2000-05-15 用于治疗癌症的海鞘素743的组合物和用途

Country Status (32)

Country Link
US (1) US8119638B2 (cg-RX-API-DMAC7.html)
EP (3) EP1716853B9 (cg-RX-API-DMAC7.html)
JP (2) JP2002544231A (cg-RX-API-DMAC7.html)
KR (1) KR20020019914A (cg-RX-API-DMAC7.html)
CN (2) CN1360503A (cg-RX-API-DMAC7.html)
AR (1) AR028476A1 (cg-RX-API-DMAC7.html)
AT (3) ATE375795T1 (cg-RX-API-DMAC7.html)
AU (2) AU777417B2 (cg-RX-API-DMAC7.html)
BG (1) BG65680B1 (cg-RX-API-DMAC7.html)
BR (1) BR0010531A (cg-RX-API-DMAC7.html)
CA (1) CA2373794C (cg-RX-API-DMAC7.html)
CY (4) CY1105818T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ301482B6 (cg-RX-API-DMAC7.html)
DE (4) DE60045720D1 (cg-RX-API-DMAC7.html)
DK (3) DK1702618T3 (cg-RX-API-DMAC7.html)
ES (2) ES2272279T3 (cg-RX-API-DMAC7.html)
FR (1) FR08C0013I2 (cg-RX-API-DMAC7.html)
HU (2) HU229866B1 (cg-RX-API-DMAC7.html)
IL (2) IL146434A0 (cg-RX-API-DMAC7.html)
LU (1) LU91418I2 (cg-RX-API-DMAC7.html)
MX (1) MXPA01011562A (cg-RX-API-DMAC7.html)
MY (1) MY164077A (cg-RX-API-DMAC7.html)
NL (1) NL300337I2 (cg-RX-API-DMAC7.html)
NO (2) NO324564B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ515423A (cg-RX-API-DMAC7.html)
PL (1) PL198185B1 (cg-RX-API-DMAC7.html)
PT (3) PT1176964E (cg-RX-API-DMAC7.html)
SI (3) SI1702618T1 (cg-RX-API-DMAC7.html)
SK (1) SK287580B6 (cg-RX-API-DMAC7.html)
TR (1) TR200103819T2 (cg-RX-API-DMAC7.html)
UA (1) UA74782C2 (cg-RX-API-DMAC7.html)
WO (1) WO2000069441A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101119750B (zh) * 2004-10-26 2013-03-06 法马马私人股份有限公司 抗癌治疗
WO2017133544A1 (zh) * 2016-02-04 2017-08-10 江苏恒瑞医药股份有限公司 一种曲贝替定的可注射胃肠外用药物组合物及其制备方法
US10538535B2 (en) 2017-04-27 2020-01-21 Pharma Mar, S.A. Antitumoral compounds

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
CN100374162C (zh) * 2000-11-06 2008-03-12 法马马有限公司 海鞘素－743在制备用于治疗肿瘤的药剂中的应用
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
KR20050038578A (ko) * 2001-10-19 2005-04-27 파르마 마르, 에스.에이. 항종양성 화합물의 암치료에 있어서의 향상된 용도
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
WO2005049031A1 (en) * 2003-11-13 2005-06-02 Pharma Mar, S.A.U. Combination
US20080255132A1 (en) * 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20080293725A1 (en) * 2004-07-09 2008-11-27 Rafael Rosell Costa Prognostic Molecular Markers
KR101188691B1 (ko) * 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
EP2023931A2 (en) * 2006-05-12 2009-02-18 Pharma Mar S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin
JP2011500046A (ja) * 2007-10-19 2011-01-06 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３治療のための予後分子マーカー
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
CN112574234B (zh) * 2019-09-27 2022-05-24 江苏恒瑞医药股份有限公司 一种海鞘素衍生物的制备方法
BR112022020812A2 (pt) 2020-04-15 2022-11-29 Ever Valinject Gmbh Composição farmacêutica compreendendo trabectedina e um aminoacido, formulação liofilizada e uma solução de injeção intravenosa compreendendo dita composição
EP3960177A1 (en) * 2020-08-26 2022-03-02 Anturec Pharmaceuticals GmbH Composition comprising ttf-ngr for use in treating soft-tissue sarcoma
US12303506B2 (en) 2022-01-20 2025-05-20 Extrovis Ag Trabectedin composition

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
JP2562162B2 (ja) * 1986-06-09 1996-12-11 ユニバーシティ・オブ・イリノイ エクテインアシジン７２９、７４３、７４５、７５９ａ、７５９ｂおよび７７０
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
GB8805268D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB9101221D0 (en) * 1991-01-19 1991-02-27 Smithkline Beecham Plc Pharmaceuticals
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5891704A (en) * 1992-11-19 1999-04-06 Anticancer, Inc. Method to produce high levels of methioninase
WO1994026250A1 (en) * 1993-05-14 1994-11-24 Depotech Corporation Method for treating neurological disorders
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
AU746713B2 (en) * 1996-11-05 2002-05-02 Children's Medical Center Corporation Methods and compositions for inhibition of angiogenesis
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
AU758100B2 (en) * 1998-04-06 2003-03-13 Board Of Trustees Of The University Of Illinois, The Semi-synthetic ecteinascidins
JP4583598B2 (ja) * 1998-05-11 2010-11-17 ファルマ・マール・ソシエダード・アノニマ エクテイナシジン７４３の代謝産物
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) * 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
DK1280809T3 (da) 2000-04-12 2005-11-07 Pharma Mar Sa Antitumorecteinascidinderivater
US7247892B2 (en) * 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
EP1356097A2 (en) * 2000-08-11 2003-10-29 City of Hope The anti-neoplastic agent et-743 inhibits trans activation by sxr
CN100374162C (zh) * 2000-11-06 2008-03-12 法马马有限公司 海鞘素－743在制备用于治疗肿瘤的药剂中的应用
EP1360337A1 (en) 2001-02-09 2003-11-12 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
AU2002242561A1 (en) 2001-03-30 2002-10-15 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
KR20050038578A (ko) 2001-10-19 2005-04-27 파르마 마르, 에스.에이. 항종양성 화합물의 암치료에 있어서의 향상된 용도
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
WO2005049031A1 (en) 2003-11-13 2005-06-02 Pharma Mar, S.A.U. Combination
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20080255132A1 (en) * 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
US20080293725A1 (en) * 2004-07-09 2008-11-27 Rafael Rosell Costa Prognostic Molecular Markers
CA2583464A1 (en) 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
JP4554684B2 (ja) * 2004-10-26 2010-09-29 ファルマ・マル・エス・アー， ソシエダッド・ユニペルソナル 抗癌治療
KR101188691B1 (ko) * 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
JP2009517403A (ja) * 2005-11-25 2009-04-30 ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュージャージー Ｐａｒｐ−１阻害剤の使用
EP2023931A2 (en) * 2006-05-12 2009-02-18 Pharma Mar S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101119750B (zh) * 2004-10-26 2013-03-06 法马马私人股份有限公司 抗癌治疗
WO2017133544A1 (zh) * 2016-02-04 2017-08-10 江苏恒瑞医药股份有限公司 一种曲贝替定的可注射胃肠外用药物组合物及其制备方法
CN107427512A (zh) * 2016-02-04 2017-12-01 江苏恒瑞医药股份有限公司 一种曲贝替定的可注射胃肠外用药物组合物及其制备方法
US10610529B2 (en) 2016-02-04 2020-04-07 Jiangsu Hengrui Medicine Co., Ltd. Trabectedin-inclusive injectable pharmaceutical composition for gastrointestinal external use and a method for manufacturing the same
TWI720117B (zh) * 2016-02-04 2021-03-01 大陸商江蘇恆瑞醫藥股份有限公司 一種曲貝替定的可注射胃腸外用藥物組成物及其製備方法
CN107427512B (zh) * 2016-02-04 2021-10-08 江苏恒瑞医药股份有限公司 一种曲贝替定的可注射胃肠外用药物组合物及其制备方法
US10538535B2 (en) 2017-04-27 2020-01-21 Pharma Mar, S.A. Antitumoral compounds
US11332480B2 (en) 2017-04-27 2022-05-17 Pharma Mar, S.A. Antitumoral compounds
US11339180B2 (en) 2017-04-27 2022-05-24 Pharma Mar, S.A. Antitumoral compounds
US11713325B2 (en) 2017-04-27 2023-08-01 Pharma Mar, S.A. Antitumoral compounds
US12384800B2 (en) 2017-04-27 2025-08-12 Pharma Mar, S.A. Antitumoral compounds

Also Published As

Publication number Publication date
PT1702618E (pt) 2008-01-11
LU91418I2 (fr) 2008-05-13
BR0010531A (pt) 2002-06-04
FR08C0013I2 (fr) 2009-10-30
HUP0201187A2 (en) 2002-09-28
SI1716853T1 (sl) 2011-10-28
IL146434A (en) 2008-03-20
SI1176964T1 (sl) 2007-02-28
EP1716853A2 (en) 2006-11-02
DE60030554T8 (de) 2008-01-10
PT1176964E (pt) 2007-01-31
IL146434A0 (en) 2002-07-25
JP5777562B2 (ja) 2015-09-09
NO2008005I1 (no) 2008-06-09
EP1716853B9 (en) 2011-09-28
NO2008005I2 (cg-RX-API-DMAC7.html) 2010-09-27
CA2373794C (en) 2005-10-11
NO20015516D0 (no) 2001-11-12
CY1105818T1 (el) 2011-02-02
PT1716853E (pt) 2011-05-12
US20070275942A1 (en) 2007-11-29
DK1176964T3 (da) 2007-01-15
CY1112753T1 (el) 2016-02-10
CN1679631A (zh) 2005-10-12
AU777417B2 (en) 2004-10-14
TR200103819T2 (tr) 2002-04-22
MXPA01011562A (es) 2002-07-30
CA2373794A1 (en) 2000-11-23
EP1702618A3 (en) 2006-12-27
EP1702618A2 (en) 2006-09-20
LU91418I9 (cg-RX-API-DMAC7.html) 2019-01-02
WO2000069441A1 (en) 2000-11-23
BG106171A (en) 2002-06-28
AU2005200180B9 (en) 2008-05-29
CY2008007I2 (el) 2009-11-04
EP1702618B1 (en) 2007-10-17
DE60036826D1 (de) 2007-11-29
HUS1500001I1 (hu) 2016-08-29
PL352931A1 (en) 2003-09-22
SK287580B6 (sk) 2011-03-04
MY164077A (en) 2017-11-30
JP2012149095A (ja) 2012-08-09
DE60030554T2 (de) 2007-09-13
HU229866B1 (en) 2014-10-28
ES2272279T3 (es) 2007-05-01
DK1702618T3 (da) 2008-02-25
AU2005200180B2 (en) 2007-12-13
SI1702618T1 (sl) 2008-02-29
EP1716853B1 (en) 2011-03-09
EP1716853A3 (en) 2006-11-15
ES2294756T3 (es) 2008-04-01
DE60036826T2 (de) 2008-08-28
NL300337I1 (nl) 2008-05-01
EP1176964B8 (en) 2007-10-10
DE60045720D1 (de) 2011-04-21
KR20020019914A (ko) 2002-03-13
NL300337I2 (nl) 2008-09-01
FR08C0013I1 (cg-RX-API-DMAC7.html) 2008-05-30
NZ515423A (en) 2004-04-30
DE122008000013I1 (de) 2008-08-07
CZ20014081A3 (cs) 2002-11-13
PL198185B1 (pl) 2008-06-30
CZ301482B6 (cs) 2010-03-17
EP1176964A1 (en) 2002-02-06
CN100477993C (zh) 2009-04-15
CY2008007I1 (el) 2009-11-04
JP2002544231A (ja) 2002-12-24
AU2005200180A1 (en) 2005-02-10
DE60030554D1 (de) 2006-10-19
DK1716853T3 (da) 2011-06-27
ATE375795T1 (de) 2007-11-15
NO20015516L (no) 2002-01-11
ATE338552T1 (de) 2006-09-15
NO324564B1 (no) 2007-11-19
ATE500830T1 (de) 2011-03-15
UA74782C2 (uk) 2006-02-15
CY1107143T1 (el) 2010-07-28
HUP0201187A3 (en) 2002-11-28
US8119638B2 (en) 2012-02-21
BG65680B1 (bg) 2009-06-30
AR028476A1 (es) 2003-05-14
EP1176964B1 (en) 2006-09-06
SK16442001A3 (sk) 2002-03-05
AU4597500A (en) 2000-12-05

Similar Documents

Publication Publication Date Title
CN1360503A (zh) 用于治疗癌症的海鞘素743的组合物和用途
RU2306933C2 (ru) Улучшенная схема применения противоопухолевого соединения в терапии рака
CN1277541C (zh) ATase抑制剂在制备使替莫唑胺对人癌细胞的毒性增效的药物组合物中的应用
CN1486193A (zh) 有效的抗肿瘤治疗方法
CN1798561A (zh) 海鞘素－743和铂抗肿瘤化合物的联合应用
JP2015057409A (ja) 多形膠芽腫の治療のためのマシテンタンを含有する組み合わせ剤
CN1897949A (zh) 包含使用et－743和紫杉醇来治疗癌症的联合疗法
CN1479622A (zh) 联合使用阿普里汀和肌肉保护剂来治疗癌症
HK1047402A (en) Compositions and uses of et743 for treating cancer
RU2266734C2 (ru) Композиции и применение ет743 для лечения злокачественных опухолей
ES2363064T3 (es) Tratamiento de cánceres del cuerpo humano utilizando et743.
NZ529801A (en) Compositions and uses of ET743 for treating cancer
CN1694691A (zh) 用蒽环类和紫杉烷类治疗转移性乳癌

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication